60 results on '"Oliver Cornely"'
Search Results
2. SARS-CoV-2 vaccination in CLL: how often is enough?
- Author
-
Oliver Cornely and Sibylle Mellinghoff
- Subjects
COVID-19 Vaccines ,SARS-CoV-2 ,Seroconversion ,Vaccination ,Immunology ,Immunity ,Humans ,COVID-19 ,Cell Biology ,Hematology ,Leukemia, Lymphocytic, Chronic, B-Cell ,Biochemistry - Published
- 2022
3. Reason and reality-identifying barriers to patient enrolment for clinical trials in invasive candidiasis
- Author
-
Sarah Heringer, Oliver Cornely, Jan Grothe, and Rosanne Sprute
- Subjects
Pharmacology ,Microbiology (medical) ,Infectious Diseases ,Antifungal Agents ,Humans ,Pharmacology (medical) ,Candidiasis, Invasive - Abstract
Objectives Enrolment of subjects to clinical trials investigating novel drugs for infectious diseases is an ongoing challenge. In this study, we evaluate factors associated with non-enrolment in treatment trials for invasive candidiasis. Methods We conducted a retrospective review of pre-screening logs of patients that were assessed for enrolment in the three clinical trials ACTIVE (NCT00413218), APX001-201 (NCT03604705) and ReSTORE (NCT03667690), investigating novel drugs for invasive candidiasis between September 2007 and August 2021 to identify reasons for study ineligibility. Results Two hundred and fifty-six patients with invasive candidiasis were identified for potential study participation with n = 154 for the ACTIVE trial, n = 89 for APX001-201 and n = 13 for ReSTORE. Half of the potential participants were unable or unwilling to consent. We further identified comorbid conditions such as hepatic or renal impairment [21 hepatic and renal cases (13.6%) in ACTIVE; 12 hepatic (13.5%) and 28 renal cases (31.5%) in APX], prior antifungal treatment [11 cases (7.1%) in ACTIVE; 16 (18.0%) in APX; 7 (38.5%) in ReSTORE] and the last positive culture obtained ≥96 h prior to dosing [1 case (0.6%) in ACTIVE; 7 (7.9%) in APX; 5 (38.5%) in ReSTORE] as relevant reasons for non-enrolment. We also identified criteria repetitively used in the analysed studies that did not contribute substantially to ineligibility rates. Ultimately, 254/256 patients (99.2%) were ineligible for enrolment in the respective trial. Conclusions This study identified barriers to enrolment in clinical trials assessing novel antifungal agents in invasive candidiasis. Identification of eligibility criteria associated with non-enrolment allows modification of future trial designs and may ultimately result in higher recruitment rates.
- Published
- 2022
4. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
- Author
-
Francesco Marchesi, Jon Salmanton-Garcia, Ziad EMARAH, Klára PIUKOVICS, Marcio Nucci, Alberto Lopez-Garcia, Zdenek Racil, Francesca Farina, Marina POPOVA, Sofia ZOMPI, Ernesta Audisio, Marie-Pierre Ledoux, Luisa VERGA, Barbora Weinbergerova, Tomas Szotkowski, Maria Silva, Nicola Stefano Fracchiolla, Nick DE JONGE, Graham Collins, Monia Marchetti, Gabriele MAGLIANO, Carolina GARCÍA-VIDAL, Monika M. BIERNAT, Jaap van Doesum, Marina MACHADO, Fatih Demirkan, Murtadha Al Khabori, Pavel Zak, Benjamin Visek, Igor STOMA, Gustavo-Adolfo MÉNDEZ, Johan Maertens, Nina KHANNA, Ildefonso Espigado, Giulia DRAGONETTI, Luana Fianchi, Maria Ilaria Del Principe, Alba CABIRTA, Irati ORMAZABAL-VÉLEZ, Ozren Jaksic, Caterina BUQUICCHIO, Valentina BONUOMO, Josip Batinić, Ali S. OMRANI, Sylvain Lamure, Olimpia Finizio, Noemí FERNÁNDEZ, Iker FALCES-ROMERO, Ola BLENNOW, Rui BERGANTIM, Natasha Ali, Sein WIN, Jens VAN PRAET, Maria Chiara Tisi, Ayten SHIRINOVA, Martin SCHÖNLEIN, Juergen PRATTES, Monica PIEDIMONTE, Verena Petzer, Milan NAVRÁTIL, Austin Kulasekararaj, Pavel Jindra, null Jiří, Andreas Glenthøj, Rita FAZZI, Cristina de Ramón, Chiara Cattaneo, Maria CALBACHO, Nathan C. BAHR, Shaimaa Saber EL-ASHWL, Raúl Córdoba, Michaela HANAKOVA, Giovanni ZAMBROTTA, Mariarita Sciumè, Stephen Booth, Raquel NUNES-RODRIGUES, Maria Vittoria SACCHI, Nicole GARCÍA-POUTÓN, Juan-Alberto MARTÍN-GONZÁLEZ, Sofya KHOSTELIDI, Stefanie GRÄFE, Laman RAHIMLI, alessandro busca, Paolo Corradini, Martin HOENIGL, Nikolai KLIMKO, Philipp Koehler, Antonio PAGLIUCA, Francesco Passamonti, Oliver Cornely, and Livio pagano
- Subjects
hemic and lymphatic diseases ,neoplasms - Abstract
Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died. Death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%). Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed. Patients with COVID-19 diagnosis between January and August 2020 had a significantly lower survival. COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment.
- Published
- 2022
5. Update on the 'Choosing Wisely' initiative in infectious diseases in Germany
- Author
-
Marylyn Addo, Frank Hanses, Jan Rupp, Oliver Cornely, and Stefan Hagel
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Review ,030204 cardiovascular system & hematology ,Communicable Diseases ,03 medical and health sciences ,Patient safety ,0302 clinical medicine ,Germany ,Health care ,medicine ,Humans ,Meningitis ,In patient ,030212 general & internal medicine ,Intensive care medicine ,Societies, Medical ,Venipuncture ,medicine.diagnostic_test ,Lumbar puncture ,business.industry ,Vaccination ,General Medicine ,medicine.disease ,Choosing Wisely ,Infectious Diseases ,Blood cultures ,Practice Guidelines as Topic ,business ,Delivery of Health Care ,Blood drawing - Abstract
Purpose The Choosing Wisely® initiative is an international campaign addressing over- and underuse of diagnostic and therapeutic measures in infectious diseases among others. Since 2016, the German Society for Infectious Diseases (DGI) has constantly designed new items in this regard. Here we report the most recent recommendations. Methods The recommendations of the DGI are part of the “Klug entscheiden” initiative of the German Society of Internal Medicine (DGIM). Topics for the new items were suggested by members of the DGI, checked for scientific evidence and consented within the DGI and the DGIM before publication. Results The new recommendations are: (1) individuals with immune-suppression, advanced liver cirrhosis or renal insufficiency should receive a dual pneumococcal vaccination. (2) In case of positive blood cultures with Candida spp. thorough diagnostics and treatment should be initiated. (3) In case of suspected meningitis, adult patients should receive dexamethasone and antibiotics immediately after venipuncture for blood cultures and before potential imaging. (4) In case of suspected meningitis a CT scan before lumbar puncture should not be ordered—except for symptoms indicating high CSF pressure or focal brain pathology or in cases of severe immune-suppression. (5) In patients with suspected severe infections, a minimum of two pairs of blood cultures should be drawn using separate venipunctures prior to antibiotic therapy—regardless of body temperature. There is no need of a minimum time interval in between the blood draws. Conclusion Applying these new Choosing Wisely® recommendations will increase patient safety and the value of health care.
- Published
- 2020
6. OUP accepted manuscript
- Author
-
Jean-Pierre Gangneux, Oliver Cornely, and Elena Daniela Serban
- Subjects
Infectious Diseases ,General Medicine - Published
- 2022
7. The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination
- Author
-
Carina Saggau, Gabriela Rios Martini, Elisa Rosati, Silja Meise, Berith Messner, Ann-Kristin Kamps, Nicole Bekel, Johannes Gigla, Ruben Rose, Mathias Voß, Ulf M. Geisen, Hayley M. Reid, Melike Sümbül, Florian Tran, Dennis K. Berner, Yascha Khodamoradi, Maria J.G.T. Vehreschild, Oliver Cornely, Philipp Koehler, Andi Krumbholz, Helmut Fickenscher, Oliver Kreuzer, Claudia Schreiber, Andre Franke, Stefan Schreiber, Bimba Hoyer, Alexander Scheffold, and Petra Bacher
- Subjects
Infectious Diseases ,SARS-CoV-2 ,Immunoglobulin G ,Vaccination ,Immunology ,Immunity ,Receptors, Antigen, T-Cell ,COVID-19 ,Humans ,Immunology and Allergy ,Antibodies, Viral ,Aged - Abstract
SARS-CoV-2 infection and vaccination generates enormous host-response heterogeneity and an age-dependent loss of immune-response quality. How the pre-exposure T cell repertoire contributes to this heterogeneity is poorly understood. We combined analysis of SARS-CoV-2-specific CD4
- Published
- 2022
8. Comment on: Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching
- Author
-
Oliver Cornely, Jan Grothe, and Rosanne Sprute
- Subjects
Pharmacology ,Microbiology (medical) ,Infectious Diseases ,Pharmacology (medical) - Published
- 2022
9. Harmonized procedure coding system for surgical procedures of five European countries (Preprint)
- Author
-
Sibylle Mellinghoff, Carolin Bruns, Rouvier Al-Monajjed, Florian Cornely, Maria Grosheva, Juergen Hampl, Carolin Jakob, Felix Koehler, Max Lechmann, Bijan Maged, Christina Otto-Lambertz, Robert Rongisch, Jule Rutz, Jon Salmanton-Garcia, Georg Schlachtenberger, Jannik Stemler, Janne Vehreschild, Sophia Wuelfing, Oliver Cornely, and Blasius Liss
- Abstract
BACKGROUND Surgical site infections (SSI) are frequent hospital acquired complications. Ongoing surveillance pro-grams evaluate the incidence of SSI worldwide. However, incidence rates are only estimated by the analyses of indicator procedures to date. OBJECTIVE To further assess procedure specific SSI rates, the harmonization of international procedure codes is necessary. METHODS We compared existing surgical procedure coding systems of five European countries (France, Ger-many, Italy, Spain, and the UK) and distributed a simplified code to all existing country-specific codes. Based on mode and extent of the surgical procedure and the surgical site, 153 codes were defined, distributed, and characterized within the presented coding system. Additionally, minimally invasive, laparoscopic or open surgical approaches were considered, whereas eye surgery and di-agnostic procedures were excluded. RESULTS A total number of 15432 surgical procedures were assigned to 153 SALT codes from 10 specialties. Almost 4000 (26%) procedure codes from the SALT coding system were classified as orthopaedic and trauma surgeries, thus this medical field represents the most diverse group within the SALT coding system, followed by abdominal surgical procedures with 2390 (15%) procedure codes. CONCLUSIONS The Europe-wide SALT procedure code gives the opportunity to harmonize big data sets containing surgical procedures from international centres, and may simplify comparability of future interna-tional trial findings.
- Published
- 2021
10. Session
- Author
-
Oliver Cornely and Laszlo Irinyi
- Subjects
Infectious Diseases ,Dermatology ,General Medicine - Published
- 2019
11. Postersession
- Author
-
Oliver Cornely
- Subjects
Infectious Diseases ,Dermatology ,General Medicine - Published
- 2019
12. 992. Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI)
- Author
-
Jose A Vazquez, Oliver Cornely, Philipp Koehler, Riina Rautemaa-Richardson, Rohit Bazaz, G Marshall Lyon, Francisco M Marty, Isabel H Gonzalez-Bocco, Rachel Miller, Thomas J Walsh, Peter Pappas, Todd P McCarty, John W Sanders, Caryn Morse, Luis Ostrosky-Zeichner, Robert Krause, Jürgen Prattes, Andrej Spec, David Andes, Oliver Witzke, Nkechi Azie, and David A Angulo
- Subjects
Infectious Diseases ,Oncology ,education - Abstract
Background Candida albicans is the predominant organism causing esophageal candidiasis (EC) and oropharyngel candidiasis (OPC). These infections may arise from subjects colonized with Candida who are predisposed due to illness, debility or a local reduction in host resistance to an overgrowth of their own indigenous flora. Patients with mucocutaneous Candida infections can be treated in the outpatient setting, yet there are limited oral treatment options available for patients who are unresponsive to or who are intolerant to currently available antifungals. Oral ibrexafungerp is an investigational broad-spectrum glucan synthase inhibitor antifungal with activity against Candida species, including azole- and echinocandin-resistant strains. A Phase 3 open-label, single-arm study of ibrexafungerp (FURI; NCT03059992) is ongoing for the treatment of patients intolerant of or with fungal disease refractory to standard antifungal therapy. Table 1. FURI Outcomes in OPC and EC Methods FURI subjects were eligible for enrollment if they had proven or probable severe mucocutaneous candidiasis, invasive candidiasis, invasive aspergillosis, or other fungal diseases with evidence of treatment failure, intolerance, or toxicity related to a currently approved standard-of-care antifungal treatment or if they were unable to receive an approved oral antifungal option (e.g., susceptibility of the organism) and a continued IV antifungal therapy was clinically undesirable or unfeasible. Results An independent Data Review Committee (DRC) provided an assessment of treatment response for 74 subjects enrolled in the FURI study from 22 centers in US, UK and EU treated with ibrexafungerp for mucocutaneous or invasive fungal infections from 2016- 2020. A total 32 subjects (43.2%) had mucocutaneous candidiasis and 24 subjects were diagnosed with OPC or EC. The percent of patients who were determined to have a complete response (CR) or partial response (PR) was 62.5%, stable disease (SD), 20.8%, and progression of disease, 16.7%. Table 1 shows outcomes by EC and OPC as determined by the DRC. Conclusion Analysis of 24 EC and OPC patients from the FURI study indicates that oral ibrexafungerp provides a favorable therapeutic response in patients with challenging mucocutaneous fungal disease and limited treatment options. Disclosures Oliver Cornely, Prof., Actelion (Consultant, Grant/Research Support)Al-Jazeera Pharmaceuticals (Consultant)Allecra Therapeutics (Consultant)Amplyx (Consultant, Grant/Research Support)Astellas (Consultant, Grant/Research Support)Basilea (Consultant, Grant/Research Support)Biocon (Consultant)Biosys (Consultant)Cidara (Consultant, Grant/Research Support)CoRe Consulting (Consultant)Da Volterra (Consultant, Grant/Research Support)DFG (German Research Foundation) (Grant/Research Support)Entasis (Consultant)F2G (Consultant, Grant/Research Support)German Federal Ministry of Research and Education (Grant/Research Support)Gilead (Consultant, Grant/Research Support)Grupo Biotoscana (Consultant)Immunic (Grant/Research Support)IQVIA (Consultant)Janssen (Grant/Research Support)Matinas (Consultant)Medicines Company (Grant/Research Support)MedPace (Consultant, Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini (Consultant)Merck/MSD (Consultant, Grant/Research Support)Molecular Partners (Consultant)MSG-ERC (Consultant)Mylan (Consultant)Nabriva (Consultant)Noxxon (Consultant)Octapharma (Consultant)Paratek (Consultant)Pfizer (Consultant, Grant/Research Support)PSI (Consultant)Roche Diagnostics (Consultant)Scynexis (Consultant, Grant/Research Support)Seres (Consultant)Shionogi (Consultant)Wiley (Blackwell) (Other Financial or Material Support) Philipp Koehler, MD, Ambu GmbH (Consultant, Speaker’s Bureau)Astellas Pharma (Speaker’s Bureau)Euopean Confederation of Medical Mycology (Speaker’s Bureau)German Federal Ministry of Research and Education (Grant/Research Support)Gilead (Consultant, Speaker’s Bureau)MSD (Speaker’s Bureau)Noxxon N.V. (Consultant)Pfizer (Speaker’s Bureau)State of North Rhine-Westphalia, Germany (Grant/Research Support) Riina Rautemaa-Richardson, DDS, PhD, FRCPath, SCYNEXIS, Inc. (Scientific Research Study Investigator) G. Marshall Lyon, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Francisco M. Marty, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Rachel Miller, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Thomas J. Walsh, MD, PhD (hon), Scynexis (Consultant, Grant/Research Support)Shionogi (Consultant, Grant/Research Support) Peter Pappas, MD, Astellas (Grant/Research Support)Cidara (Grant/Research Support, Advisor or Review Panel member)Mayne (Grant/Research Support, Advisor or Review Panel member)Merck (Grant/Research Support)SCYNEXIS, Inc. (Consultant, Grant/Research Support) Todd P. McCarty, MD, Cidara (Grant/Research Support)GenMark (Grant/Research Support, Other Financial or Material Support, Honoraria for Research Presentation)T2 Biosystems (Consultant) Caryn Morse, MD, Chimerix (Scientific Research Study Investigator)Covis Pharma (Scientific Research Study Investigator)Gilead Sciences Inc. (Scientific Research Study Investigator)Ridgeback Biotherapeutics (Scientific Research Study Investigator)Roche (Scientific Research Study Investigator)SCYNEXIS, Inc. (Scientific Research Study Investigator)Theratechnologies (Advisor or Review Panel member)Viiv (Advisor or Review Panel member) Luis Ostrosky-Zeichner, MD, Amplyx (Consultant)Cidara (Consultant)F2G (Consultant)Gilead (Grant/Research Support, Speaker’s Bureau)Pfizer (Scientific Research Study Investigator, Speaker’s Bureau)Scynexis (Grant/Research Support, Scientific Research Study Investigator)Viracor (Consultant) Jürgen Prattes, Dr, AbbVie Inc. (Shareholder)Gilead (Speaker’s Bureau)MSD (Grant/Research Support)Novo Nordisk (Shareholder)Pfizer (Advisor or Review Panel member)Stryker (Shareholder) Andrej Spec, MD, MSCI, SCYNEXIS, Inc. (Consultant, Scientific Research Study Investigator) David Andes, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Oliver Witzke, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Nkechi Azie, MD, SCYNEXIS, Inc. (Employee, Shareholder) David A. Angulo, MD, SCYNEXIS, Inc. (Employee, Shareholder)
- Published
- 2021
13. Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases
- Author
-
Marie, von Lilienfeld-Toal, Jörg Janne, Vehreschild, Oliver, Cornely, Livio, Pagano, Francesca, Compagno, and Zdenek, Racil
- Subjects
Quality of life ,Infection Control ,Infectious Disease Transmission, Patient-to-Professional ,SARS-CoV-2 ,Pneumonia, Viral ,COVID-19 ,Betacoronavirus ,Myeloproliferative disease ,Neoplasms ,Practice Guidelines as Topic ,Correspondence ,Humans ,Patient Care ,Coronavirus Infections ,Pandemics - Abstract
Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most important protection for patients with malignant disease is the best-possible control of the underlying disease.
- Published
- 2020
14. 983. Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI)
- Author
-
John W Sanders, Caryn Morse, Oliver Cornely, Philipp Koehler, Robert Krause, Jürgen Prattes, Guenter Weiss, Nkechi Azie, and David A Angulo
- Subjects
Infectious Diseases ,Oncology - Abstract
Background Candida osteoarticular infections are often preceded by candidemia with the intervertebral discs and knee joints the most common area for candidemic seeding. Candida osteomyelitis has significant morbidity and diagnosis is often delayed difficult to treat. Treatment courses are usually long and there are limited oral options available for patients who have an azole-resistant infection. Oral ibrexafungerp is an investigational broad-spectrum glucan synthase inhibitor antifungal with activity against Candida and Aspergillus species, including azole- and echinocandin-resistant strains. A Phase 3 open-label, single-arm study of ibrexafungerp (FURI; NCT03059992) is ongoing for the treatment of patients with fungal disease refractory or who intolerant of to standard of care antifungal therapy. Table 1. FURI Bone and Joint Infection Outcomes Methods FURI subjects were eligible for enrollment if they have proven or probable, severe mucocutaneous candidiasis, invasive candidiasis or invasive aspergillosis and documented evidence of failure to, intolerance to, or toxicity related to a currently approved standard-of-care antifungal treatment or can not receive approved oral antifungal options (e.g., susceptibility of the organism) or a continued IV antifungal therapy is clinically undesirable or unfeasible. Results An independent Data Review Committee (DRC) provided an assessment of treatment response for a total 74 subjects enrolled in the FURI study from 22 centers in US, UK and EU treated with ibrexafungerp for mucocutaneous or invasive fungal infections from 2016- 2020. There were 8 subjects out of the 74 subjects who were diagnosed with various bone and joint infections, 5 subjects with spondylodiscitis, 1 subject with a knee/prosthetic joint infection and 2 subjects with bone infections, one of the tibia and one of the zygomatic arch. Table 1 shows outcomes for this patient group, five (75%) patients had a clinical benefit (complete or partial response and stable response), one (12.5%) had progression of disease and one patient was indeterminate. The median days of therapy for this group was 210.5 days. Conclusion Analysis of 8 subjects from the FURI study indicates that oral ibrexafungerp provides a promising therapeutic response in option for patients with bone and/or joint infections. Disclosures Caryn Morse, MD, Chimerix (Scientific Research Study Investigator)Covis Pharma (Scientific Research Study Investigator)Gilead Sciences Inc. (Scientific Research Study Investigator)Ridgeback Biotherapeutics (Scientific Research Study Investigator)Roche (Scientific Research Study Investigator)SCYNEXIS, Inc. (Scientific Research Study Investigator)Theratechnologies (Advisor or Review Panel member)Viiv (Advisor or Review Panel member) Oliver Cornely, Prof., Actelion (Consultant, Grant/Research Support)Al-Jazeera Pharmaceuticals (Consultant)Allecra Therapeutics (Consultant)Amplyx (Consultant, Grant/Research Support)Astellas (Consultant, Grant/Research Support)Basilea (Consultant, Grant/Research Support)Biocon (Consultant)Biosys (Consultant)Cidara (Consultant, Grant/Research Support)CoRe Consulting (Consultant)Da Volterra (Consultant, Grant/Research Support)DFG (German Research Foundation) (Grant/Research Support)Entasis (Consultant)F2G (Consultant, Grant/Research Support)German Federal Ministry of Research and Education (Grant/Research Support)Gilead (Consultant, Grant/Research Support)Grupo Biotoscana (Consultant)Immunic (Grant/Research Support)IQVIA (Consultant)Janssen (Grant/Research Support)Matinas (Consultant)Medicines Company (Grant/Research Support)MedPace (Consultant, Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini (Consultant)Merck/MSD (Consultant, Grant/Research Support)Molecular Partners (Consultant)MSG-ERC (Consultant)Mylan (Consultant)Nabriva (Consultant)Noxxon (Consultant)Octapharma (Consultant)Paratek (Consultant)Pfizer (Consultant, Grant/Research Support)PSI (Consultant)Roche Diagnostics (Consultant)Scynexis (Consultant, Grant/Research Support)Seres (Consultant)Shionogi (Consultant)Wiley (Blackwell) (Other Financial or Material Support) Philipp Koehler, MD, Ambu GmbH (Consultant, Speaker’s Bureau)Astellas Pharma (Speaker’s Bureau)Euopean Confederation of Medical Mycology (Speaker’s Bureau)German Federal Ministry of Research and Education (Grant/Research Support)Gilead (Consultant, Speaker’s Bureau)MSD (Speaker’s Bureau)Noxxon N.V. (Consultant)Pfizer (Speaker’s Bureau)State of North Rhine-Westphalia, Germany (Grant/Research Support) Jürgen Prattes, Dr, AbbVie Inc. (Shareholder)Gilead (Speaker’s Bureau)MSD (Grant/Research Support)Novo Nordisk (Shareholder)Pfizer (Advisor or Review Panel member)Stryker (Shareholder) Guenter Weiss, MD, MSD (Speaker’s Bureau)Novartis (Speaker’s Bureau)Pfizer (Speaker’s Bureau)Pharmacosmos (Speaker’s Bureau)Scynexis (Scientific Research Study Investigator)Vifor (Speaker’s Bureau) Nkechi Azie, MD, SCYNEXIS, Inc. (Employee, Shareholder) David A. Angulo, MD, SCYNEXIS, Inc. (Employee, Shareholder)
- Published
- 2021
15. Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology
- Author
-
Cornelia Lass-Flörl, SILVIA CAMPOS, Glen Westall, PAOLO GROSSI, Letizia Corinna Morlacchi, AMPARO SOLE, Prof. Jens Gottlieb, Jérôme Le Pavec, M. Teresa Martin Gomez, Victor Monforte, Johanna Claustre, Carlos Cervera, Julien Coussement, Hossein Zarrinfar, Nikolaus Kneidinger, Dima Kabbani, Lorenzo Rosso, Effrossyni Gkrania-Klotsas, José Manuel Cifrián, Mathieu Puyade, Blandine Rammaert, Andrea Dell'Amore, Oliver Cornely, Saima Aslam, Shahid Husain, Oriol Manuel, and Lieven Dupont
- Subjects
Response rate (survey) ,Transplantation ,medicine.medical_specialty ,Respiratory tract infections ,business.industry ,medicine.medical_treatment ,030230 surgery ,3. Good health ,Scedosporium ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,Internal medicine ,medicine ,Lung transplantation ,030211 gastroenterology & hepatology ,Colonization ,Prospective cohort study ,business ,Contraindication - Abstract
BACKGROUND Scedosporium species and Lomentospora prolificans (S/L) are the second most common causes of invasive mold infections following Aspergillus in lung transplant recipients. METHODS We assessed the current practices on management of S/L colonization/infection of the lower respiratory tract before and after lung transplantation in a large number of lung transplant centers through an international practice survey from October 2016 to March 2017. RESULTS A total of 51 respondents from 45 lung transplant centers (17 countries, 4 continents) answered the survey (response rate 58%). S/L colonization was estimated to be detected in candidates by 48% of centers. Only 18% of the centers used a specific medium to detect S/L colonization. Scedosporium spp. colonization was a contraindication to transplantation in 10% of centers whereas L prolificans was a contraindication in 31%; 22% of centers declared having had 1-5 recipients infected with S/L in the past 5 years. CONCLUSIONS This survey gives an overview of the current practices regarding S/L colonization and infection in lung transplant centers worldwide and underscores the need of S/L culture procedure standardization before implementing prospective studies.
- Published
- 2019
16. 1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
- Author
-
Barbara D Alexander, Oliver Cornely, Peter Pappas, Rachel Miller, Jose A Vazquez, Luis Ostrosky-Zeichner, Andrej Spec, Riina Rautemaa-Richardson, Robert Krause, George R Thompson III, Caryn Morse, John W Sanders, David Andes, George Lyon, Francisco M Marty, Emily Silverman, Marisa H Miceli, Thomas F Patterson, Martin Hoenigl, Nkechi Azie, and David A Angulo
- Subjects
medicine.medical_specialty ,business.industry ,Candida esophagitis ,Disease progression ,Pathogenicity ,Interim analysis ,AcademicSubjects/MED00290 ,Infectious Diseases ,New england ,Oncology ,Open label study ,Refractory ,Internal medicine ,Poster Abstracts ,medicine ,Adverse effect ,business - Abstract
Background Candida infections resistant to currently available antifungals are an emerging global threat. Ibrexafungerp is an investigational broad-spectrum glucan synthase inhibitor antifungal with activity against Candida and Aspergillus species, including azole- and echinocandin-resistant strains. A Phase 3 open-label, single-arm study of oral ibrexafungerp (FURI) (Clinicaltrials.gov NCT03059992) is ongoing for the treatment of patients (≥18 years) with fungal diseases who are intolerant of or refractory to standard antifungal therapies. Methods An independent Data Review Committee (DRC) provided an assessment of treatment response for 41 patients. Patients were enrolled in 22 centers from 6 countries. Patients were eligible for enrollment if they had proven or probable, invasive or severe mucocutaneous candidiasis and documented evidence of failure of, intolerance to, or toxicity related to a currently approved standard-of-care antifungal treatment or could not receive approved oral antifungal options (e.g., susceptibility of the organism) and a continued IV antifungal therapy was undesirable or unfeasible. Results The 41 patients assessed had the following infection types: intra-abdominal abscesses, oropharyngeal candidiasis, esophageal candidiasis, candidemia, and others. The DRC adjudicated 23 patients (56%) as achieving complete or partial response, 11 patients (27%) maintaining stable disease, 6 patients (15%) with progression of disease and one case was considered as indeterminate. The efficacy of oral ibrexafungerp by pathogen is shown in Table 1. Ibrexafungerp was well-tolerated with the most common treatment-related adverse events being of gastrointestinal origin. No deaths due to progression of fungal disease were reported. Table 1: Ibrexafungerp Outcomes by Pathogen Conclusion Preliminary analysis of these 41 cases indicate that oral ibrexafungerp provides a favorable therapeutic response in the majority of patients with difficult to treat Candida spp. infections, including those caused by non-albicans Candida species. Disclosures Barbara D. Alexander, MD, MHS, SCYNEXIS, Inc. (Employee, Scientific Research Study Investigator, Research Grant or Support) Oliver Cornely, Prof., Actelion (Grant/Research Support)Actelion (Other Financial or Material Support, Personal fees)Al Jazeera Pharmaceuticals (Consultant)Allecra Therapeutics (Other Financial or Material Support, Personal fees)Amplyx (Other Financial or Material Support, Personal fees)Amplyx (Grant/Research Support)Astellas (Grant/Research Support)Astellas (Other Financial or Material Support, Personal fees)Basilea (Other Financial or Material Support, Personal fees)Basilea (Grant/Research Support)Biosys UK Limited (Other Financial or Material Support, Personal fees)Cidara (Other Financial or Material Support, Personal fees)Cidara (Grant/Research Support)Da Volterra (Grant/Research Support)Da Volterra (Other Financial or Material Support, Personal fees)Entasis (Other Financial or Material Support, Personal fees)F2G (Other Financial or Material Support)F2G (Grant/Research Support)Gilead (Grant/Research Support)Gilead (Other Financial or Material Support, Personal fees)Grupo Biotoscana (Other Financial or Material Support, Personal fees)Janssen Pharmaceuticals (Grant/Research Support)Matinas (Other Financial or Material Support, Personal fees)Medicines Company (Grant/Research Support)MedPace (Grant/Research Support)MedPace (Other Financial or Material Support, Personal fees)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche (Other Financial or Material Support, Personal fees)Merck/MSD (Other Financial or Material Support, Personal fees)Merck/MSD (Grant/Research Support)Mylan Pharmaceuticals (Consultant)Nabriva Therapeutics (Other Financial or Material Support, Personal fees)Octapharma (Other Financial or Material Support, Personal fees)Paratek Pharmaceuticals (Other Financial or Material Support, Personal fees)Pfizer (Other Financial or Material Support, Personal fees)Pfizer (Grant/Research Support)PSI (Other Financial or Material Support, Personal fees)Rempex (Other Financial or Material Support, Personal fees)Roche Diagnostics (Other Financial or Material Support, Personal fees)Scynexis (Other Financial or Material Support, Personal fees)Scynexis (Grant/Research Support)Seres Therapeutics (Other Financial or Material Support, Personal fees)Tetraphase (Other Financial or Material Support, Personal fees) Peter Pappas, MD, SCYNEXIS, Inc. (Consultant, Advisor or Review Panel member, Research Grant or Support) Rachel Miller, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Luis Ostrosky-Zeichner, MD, Amplyx (Scientific Research Study Investigator)Astellas (Consultant, Scientific Research Study Investigator, Other Financial or Material Support, Non-branded educational speaking)Biotoscana (Consultant, Other Financial or Material Support, Non-branded educational speaking)Cidara (Consultant, Scientific Research Study Investigator)F2G (Consultant)Gilead (Consultant)Mayne (Consultant)Octapharma (Consultant)Pfizer (Other Financial or Material Support, Non-branded educational speaking)Scynexis (Consultant, Grant/Research Support, Scientific Research Study Investigator)Stendhal (Consultant)Viracor (Consultant) Andrej Spec, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator, Advisor or Review Panel member) Riina Rautemaa-Richardson, DDS, PhD, FRCPath, SCYNEXIS, Inc. (Scientific Research Study Investigator) Robert Krause, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Caryn Morse, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) John W. Sanders, III, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) David Andes, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator, Advisor or Review Panel member) George Lyon, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator) Francisco M. Marty, MD, Allovir (Consultant)Amplyx (Consultant)Ansun (Scientific Research Study Investigator)Avir (Consultant)Cidara (Scientific Research Study Investigator)F2G (Consultant, Scientific Research Study Investigator)Kyorin (Consultant)Merck (Consultant, Grant/Research Support, Scientific Research Study Investigator)New England Journal of Medicine (Other Financial or Material Support, Honorarium for Video)Regeneron (Consultant, Scientific Research Study Investigator)ReViral (Consultant)Scynexis (Scientific Research Study Investigator)Symbio (Consultant)Takeda (Scientific Research Study Investigator)United Medical (Consultant)WHISCON (Scientific Research Study Investigator) Marisa H. Miceli, MD, FIDSA, SCYNEXIS, Inc. (Advisor or Review Panel member) Thomas F. Patterson, MD, SCYNEXIS, Inc. (Advisor or Review Panel member) Martin Hoenigl, MD, SCYNEXIS, Inc. (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member) Nkechi Azie, MD, SCYNEXIS, Inc. (Employee, Shareholder) David A. Angulo, MD, SCYNEXIS, Inc. (Employee, Shareholder)
- Published
- 2020
17. Candida-reactive T cells for the diagnosis of invasive Candida infection
- Author
-
Alexander Scheffold and Oliver Cornely
- Published
- 2018
18. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines
- Author
-
Malgorzata Mikulska, Diana Averbuch, Frederic Tissot, Catherine Cordonnier, Murat Akova, Thierry Calandra, Marcello Ceppi, Paolo Bruzzi, Claudio Viscoli, Mahmoud Aljurf, Dina Averbuch, Rosemary Barnes, Ola Blennow, Pierre-Yves Bochud, Emilio Bouza, Stephane Bretagne, Roger Brüggemann, Jordi Carratala, Simone Cesaro, Oliver Cornely, Tina Dalianis, Rafael De La Camara, Peter Donnelly, Lubos Drgona, Rafael Duarte, Hermann Einsele, Dan Engelhard, Christopher Fox, Corrado Girmenia, Andreas Groll, Dag Heldal, Jannick Helweg Larsen, Raoul Herbrecht, Hans Hirsch, Elisabeth Johnson, Galina Klyasova, Minna Koskuenvo, Katrien Lagrou, Russel E. Lewis, Per Ljungman, Johan Maertens, Georg Maschmeyer, Marcio Nucci, Christophe Padoin, Livio Pagano, Antonio Pagliuca, Zdenek Racil, Patricia Ribaud, Christine Rinaldo, Valérie Rizzi Puechal, Emmanuel Roilides, Christine Robin, Montserrat Rovira, Markus Rupp, Sonia Sanchez, Peter Schellongowski, Peter Sedlacek, Janos Sinko, Monica Slavin, Isabella Sousa Ferreira, Jan Styczynski, Katherine Ward, Anne-Therese Witschi, Mikulska, Malgorzata, Averbuch, Diana, Tissot, Frederic, Cordonnier, Catherine, Akova, Murat, Calandra, Thierry, Ceppi, Marcello, Bruzzi, Paolo, Viscoli, Claudio, Aljurf, Mahmoud, Averbuch, Dina, Barnes, Rosemary, Blennow, Ola, Bochud, Pierre-Yve, Bouza, Emilio, Bretagne, Stephane, Brüggemann, Roger, Carratala, Jordi, Cesaro, Simone, Cornely, Oliver, Dalianis, Tina, De La Camara, Rafael, Donnelly, Peter, Drgona, Lubo, Duarte, Rafael, Einsele, Hermann, Engelhard, Dan, Fox, Christopher, Girmenia, Corrado, Groll, Andrea, Heldal, Dag, Larsen, Jannick Helweg, Herbrecht, Raoul, Hirsch, Han, Johnson, Elisabeth, Klyasova, Galina, Koskuenvo, Minna, Lagrou, Katrien, Lewis, Russel E., Ljungman, Per, Maertens, Johan, Maschmeyer, Georg, Nucci, Marcio, Padoin, Christophe, Pagano, Livio, Pagliuca, Antonio, Racil, Zdenek, Ribaud, Patricia, Rinaldo, Christine, Puechal, Valérie Rizzi, Roilides, Emmanuel, Robin, Christine, Rovira, Montserrat, Rupp, Marku, Sanchez, Sonia, Schellongowski, Peter, Sedlacek, Peter, Sinko, Jano, Slavin, Monica, Ferreira, Isabella Sousa, Styczynski, Jan, Ward, Katherine, and Witschi, Anne-Therese
- Subjects
Neutropenic ,Microbiology (medical) ,Ciprofloxacin ,Febrile neutropenia ,Infection ,Levofloxacin ,Multidrug resistance (MDR) ,Prevention ,Quinolone ,medicine.medical_specialty ,Neutropenia ,Guidelines as Topic ,Infections ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Antibiotic resistance ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Ciprofloxacin, Febrile neutropenia, Infection, Levofloxacin, Multidrug resistance (MDR), Neutropenic, Prevention, Quinolone, Microbiology (medical), Infectious Diseases ,030212 general & internal medicine ,Intensive care medicine ,Infection Control ,business.industry ,Antibiotic Prophylaxis ,medicine.disease ,Anti-Bacterial Agents ,Settore MED/15 - MALATTIE DEL SANGUE ,Resistant bacteria ,Critical appraisal ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Infectious Diseases ,Hematologic Neoplasms ,030220 oncology & carcinogenesis ,Haematological cancer ,Observational study ,business ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,Fluoroquinolones - Abstract
Contains fulltext : 190513.pdf (Publisher’s version ) (Closed access) OBJECTIVES: Fluoroquinolone (FQ) prophylaxis was recommended in 2005 by European Conference on Infections in Leukemia (ECIL) for patients with prolonged neutropenia. In consideration of a worldwide increase in antibiotic resistance, the issue of FQ prophylaxis during neutropenia was re-evaluated. METHODS: Literature review of randomised controlled trials (RCT) and observational studies published in years 2006-2014 was performed. Their results were analysed in meta-analysis. Meta-regression model was applied to evaluate whether the rates of FQ resistance in community and hospital settings influenced the efficacy of FQ prophylaxis. The impact of FQ prophylaxis on colonisation and infection with resistant bacteria was reviewed. RESULTS: Two RCTs and 12 observational studies were identified. FQ prophylaxis did not have effect on mortality (pooled OR 1.01, 95%CI 0.73-1.41), but was associated with lower rate of bloodstream infections (BSI) (pooled OR 0.57, 95%CI 0.43-0.74) and episodes of fever during neutropenia (pooled OR 0.32, 95%CI 0.20-0.50). No effect of the background rate of FQ resistance on the efficacy of FQ prophylaxis was observed. In few studies, FQ prophylaxis resulted in an increased colonisation or infection with FQ- or multi-drug resistant strains. CONCLUSIONS: The possible benefits of FQ prophylaxis on BSI rate, but not on overall mortality, should be weighed against its impact in terms of toxicity and changes in local ecology in single centres.
- Published
- 2018
19. Pneumonie unter Immunsuppression: Antimikrobielle Substanzen
- Author
-
Santiago Ewig and Oliver Cornely
- Published
- 2017
20. Erreger
- Author
-
Santiago Ewig, Oliver Cornely, and Sören Gatermann
- Published
- 2017
21. Antimikrobielle Substanzen
- Author
-
Santiago Ewig and Oliver Cornely
- Published
- 2017
22. Epidemiology of Surgical Site Infections With Staphylococcus aureus in Europe: Protocol for a Retrospective, Multicenter Study (Preprint)
- Author
-
Jörg Janne Vehreschild, Blasius Janusch Liss, Oliver Cornely, and Sibylle Mellinghoff
- Abstract
BACKGROUND Surgical site infections (SSIs) are among the most common hospital acquired infections. While the incidence of SSI in certain indicator procedures is the subject of ongoing surveillance efforts in hospitals and health care systems around the world, SSI rates vary markedly within surgical categories and are poorly represented by routinely monitored indicator procedures (eg, mastectomy or hernia surgery). Therefore, relying on indicator procedures to estimate the burden of SSI is imprecise and introduces bias as hospitals may take special precautions to achieve lower SSI rates. The most common cause of SSI is Staphylococcus aureus (S. aureus), as recently confirmed by a Europe-wide point-prevalence study conducted by the European Centre for Disease Prevention and Control (ECDC). OBJECTIVE The primary objective of this study is to determine the overall and procedure-specific incidence of S. aureus SSI in Europe. Secondary objectives are the overall and procedure-specific outcomes as well as the economic burden of S. aureus SSI in Europe. Explorative objectives are to characterize the composition of the surgical patient population and to estimate the number of patients at risk for S. aureus SSI. METHODS A retrospective, multinational, multicenter cohort study (Staphylococcus aureus Surgical Site Infection Multinational Epidemiology in Europe [SALT] study) with a nested case-control part will be conducted. The study will include all surgical procedures at a participating center in order to prevent selection bias and strengthen the understanding of SSI risk by determining the incidence for all common surgical procedures. Data will be assessed in the cohort population, including 150,000 adult patients who underwent any surgical procedure in 2016, and the case-control population. We will match patients establishing S. aureus SSI 1:1 with controls from the same center. Data on demographics, surgery, and microbiology will be exported from electronic files. More detailed data will be captured from the case-control population. The SALT study will include 13 major or academic surgical centers in Europe, comprising 3 in France, 4 in Germany, 2 in Italy, 3 in Spain, and 1 in the United Kingdom. Sites were selected using a feasibility questionnaire. RESULTS The SALT study is currently recruiting patients. The aim is to complete recruitment in February 2018 and to close the database in September 2018. The final results are expected by the end of 2018. CONCLUSIONS Results of the SALT study will help to better understand the precise risk of certain procedures. They will also provide insight into the overall and procedure-specific incidence and outcome as well as the economic burden of S. aureus SSI in Europe. Findings of the study may help guide the design of clinical trials for S. aureus vaccines. CLINICALTRIAL ClinicalTrials.gov NCT03353532; https://clinicaltrials.gov/ct2/show/NCT03353532 (Archived by WebCite at http://www.webcitation.org/6xAK3gVmO)
- Published
- 2017
23. Pneumonie unter Neutropenie
- Author
-
Santiago Ewig and Oliver Cornely
- Published
- 2017
24. Correction
- Author
-
Oliver Cornely
- Subjects
General Medicine ,Applied Microbiology and Biotechnology ,Microbiology - Published
- 2019
25. 43rd Annual Meeting of the German-Speaking Mycological Society (DMykG)
- Author
-
Oliver Cornely
- Subjects
Infectious Diseases ,Dermatology ,General Medicine - Published
- 2009
26. Fungal endocarditis
- Author
-
Oliver Cornely and Yoav Keynan
- Subjects
Infectious Diseases - Published
- 2007
27. Mucormycosis
- Author
-
Oliver Cornely
- Published
- 2011
28. Idiotype vaccination for Non-Hodgkin lymphoma
- Author
-
Vera Ossendorf, Oliver Cornely, Andreas Draube, Ina Monsef, Andreas Engert, and Nicole Skoetz
- Published
- 2011
29. Infektiologie
- Author
-
Matthias Kochanek, Guido Michels, Gerd Fätkenheuer, Oliver Cornely, Ute Aurbach, Harald Seifert, Christian Gutschow, Dirk Waldschmidt, Jan Rybniker, Emmanouil Skouras, Maria J.G.T. Vehreschild, and Janne Vehreschild
- Published
- 2011
30. Onkologie
- Author
-
Matthias Kochanek, Oliver Cornely, and Guido Michels
- Published
- 2011
31. Onkologie
- Author
-
Matthias Kochanek, Oliver Cornely, and Guido Michels
- Published
- 2010
32. Infektiologie
- Author
-
Matthias Kochanek, Guido Michels, Susann Koch, Gerd Fätkenheuer, Oliver Cornely, Ute Aurbach, Harald Seifert, Christian Gutschow, Dirk Waldschmitt, Gero von Gersdorff, Jan Rybniker, Emmanouil Skouras, Maria Rüping, and Janne Vehreschild
- Published
- 2010
33. Adressenverzeichnis
- Author
-
Michael Böhm, Michael Hallek, Wolff Schmiegel, Guido Adler, Ali-Asa Alexander Aghdassi, Hans-Dieter Allescher, Bruno Allolio, Peter Angerer, C.E. Angermann, Christina Bähr, Daniel C. Baumgart, Claudia Bausewein, F. Ulrich Beil, Dirk Beuckelmann, Felix Beuschlein, Eberhard Blind, Christoph Bode, Ulrich Bogdahn, Christian Bojarski, Carsten Bokemeyer, Peter Bottermann, Thorsten Brechmann, Gerd-Rüdiger Burmester, Meinhard Classen, Oliver Cornely, Paula Cramer, Bodo Cremers, Volker Diehl, Annette Dieing, Markus Dietlein, Hartmut Döhner, Manfred O. Doss, A. Dünne, Andreas Engert, Georg Ertl, Gerd Fätkenheuer, Jürgen Floege, Andreas Franke, N. Frickhofen, Th. Gain, Jan Galle, Peter R. Galle, Birgit Gathof, Angela Gause, Guido Gerken, Beate Gleissner, Burkhard Göke, Rüdiger Göke, Ullrich Graeven, A. Greinacher, Friedrich Grimminger, Wolfgang Ludwig Gross, Peter Gross, Frank Grünhage, Andreas Günther, Peter Hanrath, Werner E. Hansen, Pia Hartmann, M. Haupts, Dieter Häussinger, Ekkehart Heidbreder, Michael Heike, Robert Heinrich, Stephan Heller, Bernhard Hellmich, Stefan Heringlake, Andreas Hochhaus, Stephan Hollerbach, Uta C. Hoppe, Walter H. Hörl, Dieter Horstkotte, Frank Isken, Rolf-Dieter Issels, Franz Jakob, Tomas Jelinek, Christoph Jochum, Stephan Kanzler, U. Keilholz, Michael Kindermann, Beate Klimm, Günther Klotz, Stefan Tobias Knop, Kurt Kochsiek, Volker Köllner, Hans-Jochem Kolb, Christian Kollmannsberger, Matthias Kraft, Karl-Anton Kreuzer, Heyo Kroemer, Wolfgang Kruis, Markus Kuczyk, Uwe Kühl, Anja Kwetkat, Frank Lammert, Hauke Lang, Ulrich Laufs, Wolfgang Lepper, Markus Lerch, Andreas Link, Andreas van de Loo, Carmen Loquai, Christoph Maack, Michael Peter Manns, Uta Merle, Christian Mewis, null Mertens, Susanne Milhorst, Martin Moser, Harald Morr, Joachim Mössner, Bruno Neu, Horst Neuhaus, Georg Nickenig, Eberhard Nieschlag, Thurid Nolte, Dennis Nowak, Horst Olschewski, Catrin Palm, Klaus G. Parhofer, R. Paschke, Georg Peters, Andreas Pfeiffer, Johannes Pfeilschifter, Michael Pfreundschuh, Michael Philipper, Gerd Pommer, Kurt Possinger, Christian Pox, Lukas Radbruch, Guliano Ramadori, Frank Reichenberger, Anke Reinacher-Schick, Martin Reincke, Marcel Reiser, Markus Reiser, Dieter Rosskopf, Andrea Rubbert, Bernd Salzberger, Tilman Sauerbruch, Ludwig Schaaf, V. Schächinger, Wolfgang von Scheidt, Sebastian Schellong, W. Schepp, Harald Schicha, Uwe Siegfried Schlegel, Roland Schmid, Heinz-Josef Schmitt, Hans-Joachim Schmoll, Jürgen Schölmerich, Heinz-Peter Schultheiss, Richard Schulz, Heribert Schunkert, Werner Seeger, Harald Seifert, Hanns Martin Seitz (Emeritus), H. Serve, Kai Severin, Dirk Skowasch, Michael Spannagl, Peter Staib, Ulrich Stölzel, Christian Straßburg, W. Stremmel, Norbert Suttorp, Christian von Tirpitz, Joachim Thiery, Christian Trautwein, Klaus-Henning Usadel, Hans-Georg Velcovsky, Ulrich Wahnschaffe, Hans-Dieter Walmrath, Ronald Walshe, Christoph Wanner, Hermann Wasmuth, Joachim Weil, Michael Weiß, Clemens Wendtner, Jochen A. Werner, Bertram Wiedenmann, Jörg Willert, Jürgen Wolf, Andreas Zeiher, Martin Zeitz, Stefan Zeuzem, Walter Zidek, Thomas Zilker, Michael Zitzmann, and Carsten Zwick
- Published
- 2009
34. Onychomykose
- Author
-
Claus Seebacher, Jochen Brasch, Dietrich Abeck, Oliver Cornely, Isaak Effendy, Gabriele Ginter-Hanselmayer, Norbert Haake, Gudrun Hamm, Uta-Christina Hipler, Herbert Hof, Hans Christian Korting, Peter Mayser, Markus Ruhnke, Kurt-Heiner Schlacke, and Hans-Jörgen Tietz
- Subjects
Dermatology - Published
- 2007
35. Cornely OA et al (Clin Infect Dis 2015; 61:324–31)
- Author
-
Oliver Cornely
- Subjects
Microbiology (medical) ,Infectious Diseases - Published
- 2015
36. Corrigendum
- Author
-
Oliver Cornely and Isaak Effendy
- Subjects
Infectious Diseases ,Dermatology ,General Medicine - Published
- 2015
37. Correction: Combination Antifungal Therapy for Invasive Aspergillosis
- Author
-
Oliver Cornely
- Subjects
Internal Medicine ,General Medicine - Published
- 2015
38. Antiviral agents for prophylaxis of herpesviridae infections in patients with haematological malignancies
- Author
-
Sven Trelle, Julia Bohlius, Nicole Skoetz, Guido Schwarzer, Oliver Cornely, and Andreas Engert
- Published
- 2004
39. Aspergillus to Zygomycetes: Causes, Risk Factors, Prevention, and Treatment of Invasive Fungal Infections
- Author
-
Oliver Cornely
- Subjects
Microbiology (medical) ,Infectious Diseases ,General Medicine - Published
- 2008
40. Frühzeitiges und gezieltes Handeln verbessert Überlebenschancen
- Author
-
Oliver Cornely
- Abstract
Invasive Pilzinfektionen sind eine der Hauptursachen erhöhter Morbidität und Letalität von Tumorpatienten mit einer Remissions-induzierenden Chemotherapie. Der frühe Einsatz von Antimykotika ist zwingend, um die Überlebenschancen der von Pilzinfektionen betroffenen Patienten zu verbessern. Wir sprachen mit Prof. Oliver Cornely über seine Erfahrungen an der Kölner Universitätsklinik.
- Published
- 2010
41. Factors influencing pharmacokinetics of prophylactic posaconazole oral solution in patients with acute myeloid leukemia or myelodysplastic syndrome
- Author
-
Vehreschild, J. -J, Mueller, C., Farowski, F., Vehreschild, M. J. G. T., Oliver Cornely, Fuhr, U., Kreuzer, K. -A, Hallek, M., and Kohl, V.
42. EQUAL Mucormycosis score 2018: An ECMM score derived from current gidelines to measure QUALity of mucormycosis management in hematology
- Author
-
Koehler, P., Mellinghoff, S., Alanio, A., Arenz, D., Hoenigl, M., Lagrou, K., Lass-Floerl, C., Meis, J., Richardson, M., and Oliver Cornely
43. Networking across Europe: The excellence centers of the European confederation of medical mycology
- Author
-
Lass-Florl, C., Guinea, J., Herbrecht, R., Lagrou, K., Lewis, J., Verweij, P., and Oliver Cornely
44. Evaluation of an Infectious Disease Consultancy Program in a German University Hospital
- Author
-
Vehreschild, J., Faetkenheuer, G., Morgen, G., Oliver Cornely, Hartmann, P., Koch, S., Kalka-Moll, W., Wyen, C., Vehreschild, M., Lehmann, C., Gillor, D., Seifert, H., and Jung, N.
45. The Epidemiology of Invasive Aspergillosis and Resistance Patterns of Aspergillus spp. in Germany - interim Analysis of the SEPIA Study
- Author
-
Vehreschild, M., Hamprecht, A., Adam, T., Bader, O., Becker, C., Bekeredjian-Ding, I., Buchtheidt, D., Doelken, G., Elias, J., Haase, G., Hahn-Ast, C., Karthaus, M., Kekule, A., Krause, S., Neumann, S., Keller, P., Kiehl, M., Rohde, H., La Rosee, P., Ruhnke, M., Schalk, E., Schafhausen, P., Schwartz, S., Silling, G., Schulz, K., Staib, P., Ullmann, A., Weber, T., and Oliver Cornely
46. CLINICAL CHARACTERISTICS AND OUTCOME OF INVASIVE INFECTIONS DUE TO SAPROCHAETE SPECIES IN PATIENTS AFFECTED BY HEMATOLOGICAL MALIGNANCIES. A MULTI-CENTER STUDY ON BEHALF OF SEIFEM/FUNGISCOPE REGISTRY
- Author
-
Del Principe, M. I., Criscuolo, M., Seidel, D., Dargenio, M., Racil, Z., Piedimonte, M., Marchesi, F., Nadali, G., Koehler, P., Fracchiolla, N., Cattaneo, C., Klimko, N., Spolzino, A., Karapinar, D. Yilmaz, Demiraslan, H., Duarte, R., Demeter, J., Stanziani, M., Melillo, L., Basilico, C. M., Cesaro, S., Paterno, G., Oliver Cornely, Califano, C., Delia, M., Busca, A., and Pagano, L.
47. Novel highly potent CD4bs bNAb with restricted pathway to HIV-1 escape
- Author
-
Schommers, P., Gruell, H., Abernathy, M. E., Dingens, A. S., Tran, M-K, Gristick, H. B., Barnes, C. O., Schoofs, T., Schlotz, M., Vanshylla, K., Kreer, C., Weiland, D., Holtick, U., Scheid, C., Valter, M. M., Gils, M. J., Sanders, R. W., Vehreschild, J. J., Oliver Cornely, Lehmann, C., Faetkenheuer, G., Seaman, M. S., Bloom, J. D., Bjorkman, P. J., and Klein, F.
- Abstract
Purpose: Broadly HIV-1 neutralizing antibodies (bNAbs) can suppress viremia in humans and represent a novel approach for effective immunotherapy. However, bNAb monotherapy selects for antibody-resistant viral variants. Thus, we focused on the identification of new antibody combinations and/or novel bNAbs that restrict pathways of HIV-1 escape. Methods: We screened HIV-1 positive patients for their neutralizing capacities. Following, we performed single cell sorting and PCR of HIV-1 Env-reactive mature B cells of identified elite neutralizers. Found antibodies were tested for neutralization and binding capacities in vitro. Further, their antiviral activity was tested in an HIV-1 infected humanized mouse model. Results: Here we report the isolation of antibody 1–18, a VH1–46-encoded CD4 binding site (CD4bs) bNAb identified in an individual ranking among the top 1% neutralizers of 2,274 HIV-1-infected subjects. Tested on a 119-virus panel, 1–18 showed to be exceptionally broad and potent with a coverage of 97% and a mean IC50 of 0.048 lg/mL, exceeding the activity of most potent CD4bs bNAbs described to-date. A 2.4 Å cryo-EM structure of 1–18 bound to a native-like Env trimer revealed that it interacts with HIV-1 env similar to other CD4bs bNAbs, but includes additional contacts to the V3 loop of the adjacent protomer. Notably, in vitro, 1–18 maintained activity against viruses carrying mutations associated with escape from VRC01-class bNAbs. Further, its HIV-1 env wide escape profile differed critically from other CD4bs bNAbs. In humanized mice, monotherapy with 1–18 was sufficient to prevent the development of viral escape variants that rapidly emerged during treatment with other CD4bs bNAbs. Finally, 1–18 overcame classical HIV-1 mutations that are driven by VRC01-like bNAbs in vivo. Conclusion: 1–18 is a highly potent and broad bNAb that restricts escape and overcomes frequent CD4bs escape pathways, providing new options for bNAb combinations to prevent and treat HIV-1 infection.
48. Antifungal prophylaxis with posaconazole and micafungin bridging in allogeneic SCT recipients
- Author
-
Vehreschild, M. J. G., Von-Bergwelt, M., Tran, L., Shimabukuro-Vornhagen, A., Wisplinghoff, H., Bangard, C., Oliver Cornely, and Vehreschild, J. J.
49. Fungiscope - state of affairs
- Author
-
Vehreschild, M. J. G. T., Heinz, W. J., Hamprecht, A., Fischer, G., Hoog, S., Vehreschild, J. -J, and Oliver Cornely
50. Intracellular concentrations of anidulafungin and micafungin
- Author
-
Farowski, F., Mueller, C., Vehreschild, M. J. G. T., Vehreschild, J. J., and Oliver Cornely
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.